Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases - Report - MDSpire
Advertisement
Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases
Clinical Report: Combined complement inhibition and BAFF/APRIL targeting in advanced IgA nephropathy and IgA vasculitis nephritis
Background
Rapidly progressive IgAN and IgAVN are associated with severe renal impairment and poor outcomes. Both conditions share pathogenic mechanisms, including the deposition of galactose-deficient IgA1 and complement system activation. Current treatment strategies remain uncertain.
Data Highlights
No numerical data is available in the source material.
Key Findings
Both patients had rapidly progressive crescentic disease with significant proteinuria.
Sequential therapy included eculizumab, iptacopan, and telitacicept.
After treatment, one patient showed a decrease in proteinuria from 5.72 g/day to 1.55 g/day.
Both patients experienced stabilization of kidney function during follow-up.
Clinical Implications
The cases presented indicate that multi-pathway targeted therapy may be considered for patients with aggressive forms of IgAN and IgAVN.
